A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.
Early data are promising, but the upcoming phase 2 trial has questions to answer.
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.